Clinical trials: Mosquito-Borne Diseases
Malaria
Dose Escalation PfSPZ-CVac
Background: People get malaria from bites from infected mosquitos. Researchers are studying a vaccine strategy. They will give people malaria parasites by injecting them with live infectious malaria parasites with antimalarial…
- Trial name
- NCT03083847
- Testing
- Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children
In 2005-2006, a clinical trial was carried out to test safety, tolerability and efficacy of the combination chlorproguanil-dapsone+artesunate (CD+A): 800 children aged 12-59 months with uncomplicated P.
- Trial name
- NCT00461578
- Testing
- Chlorproguanil-dapsone + artesunate
- Where
- Rwanda
- Volunteers
- 800 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Chikungunya
Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Reunion Island was struck by a severe Chikungunya outbreak in 2005-2006. Three hundred and seven Chikungunya patients were evaluated by 4 rheumatologists 2 months after the initial infection (RHUMATOCHIK study).
- Trial name
- ChikRhuma15 (NCT04838574)
- Testing
- 15 years Follow-up group
- Where
- 3 sites in Reunion
- Volunteers
- 152 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Anemia, Iron Deficiency
Iron and Prebiotics Fortification in Kenyan Infants
Iron deficiency and anemia are health issues affecting mainly infants and women in developing countries. Iron deficiency in infancy can have long-lasting impact on cognitive and motor development of the child.
- Conditions
- Anemia, Iron Deficiency, Diarrhea, Malaria
- Trial name
- Iro'n'Pre (NCT02118402)
- Testing
- Fortified maize porridge
- Where
- Kenya
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
MALARIA, FALCIPARUM
In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria
This study was designed to determine the efficacy of both artemether-lumefantrine and artesunate-amodiaquine (but not to compare the efficacies of the two drugs) for the treatment of uncomplicated Plasmodium falciparum malaria at…
- Trial name
- NCT02637128
- Testing
- artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ)
- Where
- Malawi
- Volunteers
- 452 people
- Sponsor
- Centers for Disease Control and Prevention
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Japanese Encephalitis, Hepatitis A
Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines
This study is to assess the safety and immunogenicity of three consecutive lots of JE-CV in toddlers aged 12-18 months. Primary objective: To demonstrate the bio-equivalence of three lots of JE-CV vaccine manufactured by sanofi…
- Trial name
- NCT00735644
- Testing
- Japanese encephalitis vaccine, Japanese encephalitis vaccine (Acambis), Hepatitis A vaccine
- Where
- 8 sites in Philippines, Thailand
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rift Valley Fever
Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)
The goal of this clinical trial is to learn if ChAdOx1 RVF, a candidate vaccine against RVF, provides an adequate immune response and determine its safety among Kenyan adults.
- Trial name
- RVF003 (NCT06799234)
- Testing
- ChAdOx1 RVF, Rabies Vaccine
- Where
- Kenya
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Normal Immunological Parameters Among Healthy Volunteers in Kambila, Mali
This study will determine the immune response to malaria infection in healthy volunteers compared with malaria patients. Malaria affects millions of people in Mali and Africa.
- Trial name
- NCT00471302
- Where
- Mali
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria Falciparum
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy…
- Trial name
- LARC-Tu (NCT06862453)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge (7G8)
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, HIV
Artemether/Lumefantrine and Nevirapine Interaction Study in HIV-infected Adults
Despite the clinical significance of potential interactions between antimalarials and antiretrovirals, no drug interaction studies have been published and there is an urgent need to address this gap in current knowledge.
- Trial name
- NCT00790881
- Testing
- Artemether/Lumefantrine, Artemether/ lumefantrine
- Where
- South Africa
- Volunteers
- 36 people
- Sponsor
- University of Cape Town
Malaria
Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men
Animal and human studies have shown that the prime-boost immunization strategy using malaria antigens expressed in plasmid or viral vectors induces strong cellular immune responses.
- Trial name
- NCT00121771
- Testing
- FP9 CS, MVA CS
- Where
- The Gambia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Dengue, Dengue With Warning Signs
Anakinra in Dengue With Hyperinflammation ( AnaDen )
This study aims to evaluate the effect of anakinra in dengue patients with hyperinflammation as compared to placebo Primary Objective: To evaluate the efficacy of Anakinra in moderate-severe dengue patients with…
- Conditions
- Dengue, Dengue With Warning Signs, Severe Dengue, Anakinra
- Trial name
- NCT05611710
- Testing
- Anakinra
- Where
- Vietnam
- Volunteers
- 160 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Arbovirus Infections, Respiratory Infection Virus
Cohort Study of Arbovirus and Other Emerging Virus Infections in Fiji: AEVI-Fiji Cohort.
Background: Fiji, an archipelago in the South Pacific comprising 332 islands distributed among 4 health administrative divisions (Central, Western, Eastern, Northern), is particularly vulnerable to the (re-)emergence of…
- Trial name
- AEVI-Fiji (NCT07229677)
- Where
- Fiji
- Volunteers
- 910 people, healthy volunteers welcome
- Sponsor
- Fiji National University
Malaria
Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic Areas
The purpose of this trial is to assess the safety and immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP candidate vaccines in healthy adult volunteers in a malaria endemic region.
- Trial name
- NCT01379430
- Testing
- AdCh63 ME-TRAP followed by MVA ME-TRAP
- Where
- Kenya
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Zika Virus
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
This clinical study will evaluate the safety, tolerability and reactogenicity of mRNA-1893 Zika vaccines in flavivirus seronegative and flavivirus seropositive participants
- Trial name
- NCT04064905
- Testing
- mRNA-1893
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Malaria
Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers
OZ439 is a novel, synthetic trioxolane medicine which is related to artemisinin, but has the advantage of a longer elimination half-life so is being developed to be administered together with a potential partner drug e.g.
- Trial name
- NCT01615822
- Testing
- OZ439 100mg, OZ439 400mg, MQ 250 mg, single dose
- Where
- South Africa
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Plasmodium Falciparum Malaria
AMA1-C1/Alhydrogel + CpG 7909 for Malaria
The purpose of this study is to test an experimental malaria vaccine in about 75 healthy adults, 18-45 years of age. The study will also test an experimental adjuvant which is a material added to a vaccine to help the body make…
- Trial name
- NCT00344539
- Testing
- AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Virus Infection
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
This is an observational, non-interventional, test-negative case-control (TNCC) study to estimate the vaccine effectiveness of VLA1553 against Chikungunya virus in a real-world setting.
- Trial name
- NCT07347002
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 3 sites in Brazil
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Plasmodium Falciparum
Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.
The candidate malaria vaccine RTS,S/AS02A developed by GSK Biologicals demonstrated 30% efficacy against clinical episodes of malaria and approximately 58% efficacy against severe malaria disease.
- Trial name
- NCT00197054
- Testing
- RTS, S/AS01B, RTS, S/AS02A, Rabipur (Rabies) Vaccine
- Where
- Kenya
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.